Around 90% of drugs entering clinical trials fail. What if we could dramatically reduce that risk before a molecule ever reaches a lab?
- 5 days ago
- 1 min read
That question sits at the heart of OmnigeniQ, an Australian, female-founded biotech whose origins lie not in pharma, but in space. The company’s Deterministic Intelligence platform grew out of NASA-linked research that was looking into insulin production in non-gravity environments, and where understanding how proteins behave under physical constraints was mission-critical.
Those same physics-based principles now underpin OmnigeniQ’s approach to drug discovery, enabling proteins to be computed in their true, dynamic state rather than inferred from predicted or static data.
Palin Communications supported a profile-raising earned media program securing coverage across ABC, Forbes Australia, PharmaVoice, Drug Target Review, BioWorld and Pulse.IT. The campaign exceeded awareness KPIs and positioned OmnigeniQ’s all-female team as credible voices disrupting the future of drug development.
